Amgen CEO Bradway says AI reshapes drug discovery and development
PUBT · 22h ago
Share
Listen to the news
- Amgen CEO Bob Bradway told Bain’s Winning with AI podcast that AI is reshaping biotechnology, with broad impact across the drug lifecycle.
- Bradway said the company invested early in AI and data science, positioning it to apply the technology across its operations.
- He framed AI as a catalyst for change in how medicines are discovered, developed, manufactured, and delivered to patients.
- The interview focused on scaling organizational transformation to support wider AI deployment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved